血清肿瘤标志物联合检测在肺癌诊断中的应用

The diagnostic utility of combined determination of CYFRA21-1,NSE,CEA,β_2-MG in patients with lung cancer

目的 :探讨血清19片段角蛋白(CYFRA21 -1)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、β2 微球蛋白(β2-MG)联合检测提高肺癌的阳性率 ,为临床提供早期诊断、治疗的依据。方法 :采用电化学发光和免疫比浊法检测155例肺癌、72例肺良性疾病和50例正常人血清CYFRA21 -1、NSE、CEA和β2-MG的水平。结果 :肺癌4项标志物联合检测阳性率明显高于肺良性疾病组和健康人正常对照组 ,其中CYFRA21 -1阳性率以鳞癌最高(77.7 %),与其它型肺癌存在显著差异。NSE阳性率以小细胞性肺癌最高(78.4 %) ,与其它型肺癌存在显著差异。结论 :CYFRA21 -1、NSE、CEA、β2-MG是诊断肺癌有价值的肿瘤标志物组合 ,有助于提高肺癌诊断的阳性率。

Objective: To explore the combine determination of CYFRA21-1,NSE,CEA?β2-MG in serum to improve the positive rate in detection of lung cancer,and offer the evidence for clinical diagnose and therapy in early stages.Methods: Serum levels of CYFRA21-1,NSE,CEA?β2-MG were obtained in 155 cases of lung cancer,72cases of benign lung disease and 50 cases of normal by electric chemilluminescent and immunonephelometric method. Results:The combined determination of four tumor markers in the group with lung cancer had a higher positive rate than control.The highest positive rates were 77.7% for CYFRA21-1 in the detection of squamouscell carcinoma,78.4%for NSE in small cell lung cancer,and they were significantly difference from the other patterns of lung cancer respectively.Conclusion: They are reliable tumor markers in diagnosing lung cancer,and helpful to improve the diagnostic positive rate,sensitivity and accuracy.